全文获取类型
收费全文 | 35675篇 |
免费 | 2610篇 |
国内免费 | 185篇 |
专业分类
耳鼻咽喉 | 377篇 |
儿科学 | 879篇 |
妇产科学 | 605篇 |
基础医学 | 4118篇 |
口腔科学 | 690篇 |
临床医学 | 3627篇 |
内科学 | 8439篇 |
皮肤病学 | 523篇 |
神经病学 | 3279篇 |
特种医学 | 1115篇 |
外国民族医学 | 2篇 |
外科学 | 5695篇 |
综合类 | 618篇 |
一般理论 | 27篇 |
预防医学 | 2861篇 |
眼科学 | 740篇 |
药学 | 2303篇 |
中国医学 | 49篇 |
肿瘤学 | 2523篇 |
出版年
2023年 | 189篇 |
2022年 | 294篇 |
2021年 | 808篇 |
2020年 | 454篇 |
2019年 | 780篇 |
2018年 | 919篇 |
2017年 | 635篇 |
2016年 | 619篇 |
2015年 | 810篇 |
2014年 | 1114篇 |
2013年 | 1562篇 |
2012年 | 2350篇 |
2011年 | 2357篇 |
2010年 | 1356篇 |
2009年 | 1162篇 |
2008年 | 1975篇 |
2007年 | 2130篇 |
2006年 | 2028篇 |
2005年 | 2066篇 |
2004年 | 1935篇 |
2003年 | 1781篇 |
2002年 | 1738篇 |
2001年 | 477篇 |
2000年 | 403篇 |
1999年 | 458篇 |
1998年 | 393篇 |
1997年 | 306篇 |
1996年 | 313篇 |
1995年 | 257篇 |
1994年 | 215篇 |
1993年 | 209篇 |
1992年 | 297篇 |
1991年 | 254篇 |
1990年 | 278篇 |
1989年 | 218篇 |
1988年 | 239篇 |
1987年 | 224篇 |
1986年 | 223篇 |
1985年 | 213篇 |
1984年 | 227篇 |
1983年 | 228篇 |
1982年 | 229篇 |
1981年 | 216篇 |
1980年 | 219篇 |
1979年 | 217篇 |
1978年 | 170篇 |
1977年 | 138篇 |
1976年 | 147篇 |
1974年 | 161篇 |
1973年 | 136篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Cromb Amandine Le Loarer Franois Sitbon Maxime Italiano Antoine Stoeckle Eberhard Buy Xavier Kind Michle 《European radiology》2020,30(5):2413-2424
European Radiology - The strongest adverse prognostic factor in myxoid/round cell liposarcomas (MRC-LPS) is the presence of a round cell component above 5% within the tumor bulk. Its identification... 相似文献
3.
Selwyn Arlington Headley Nayara Emily Viana Mariana de Mello Zanim Michelazzo Ana Aparecida Correa Xavier Cícero Júlio Silva Costa Felipe Hideki Ogo de Pinho Marcelo Diniz dos Santos 《Transboundary and Emerging Diseases》2020,67(Z2):49-59
Neorickettsia helminthoeca (NH), the agent of salmon poisoning disease or canine neorickettiosis (CN), is a bacterial endosymbiont of the nematode Nanophyetus salmincola, and infections are spreading among specific fish‐eating mammalians. This article describes the pathologic and immunohistochemical findings associated with spontaneous NH‐induced infections in dogs from Southern Brazil. The principal pathologic findings were hypertrophy of Peyer patches and lymphadenopathy with lymphocytic proliferation, chronic interstitial pneumonia, and chronic enteritis associated with positive intralesional immunoreactivity to antigens of NH within macrophages and histiocytes. Positive immunoreactivity against canine parvovirus‐2 (CPV‐2) or/and canine distemper virus was not detected in the evaluated intestinal segments or in the samples from the cerebellum and lungs, respectively, from the dogs evaluated. These findings demonstrated that NH was involved in the enteric, pulmonary, and lymphoid lesions herein described, and provide additional information to confirm the occurrence of this bacterial endosymbiont within this geographical location. It is proposed that chronic pneumonia should be considered as a pathologic manifestation of NH‐induced infections. Additionally, our results show that the occurrences of CN seem to be underdiagnosed in Southern Brazil due to the confusion with the incidence of CPV‐2. 相似文献
4.
5.
Pierre Tiberghien Xavier de Lamballerie Pascal Morel Pierre Gallian Karine Lacombe Yazdan Yazdanpanah 《Vox sanguinis》2020,115(6):488-494
Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number of COVID-19 cases escalates steeply worldwide. Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2-neutralizing Ab titres in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution, may reduce the frequency of patient deterioration, and thereby COVID-19 mortality. 相似文献
6.
7.
Geneticists have, for years, understood the nature of genome‐wide association studies using common genomic variants. Recently, however, focus has shifted to the analysis of rare variants. This presents potential problems for researchers, as rare variants do not always behave in the same way common variants do, sometimes rendering decades of solid intuition moot. In this paper, we present examples of the differences between common and rare variants. We show why one must be significantly more careful about the origin of rare variants, and how failing to do so can lead to highly inflated type I error. We then explain how to best avoid such concerns with careful understanding and study design. Additionally, we demonstrate that a seemingly low error rate in next‐generation sequencing can dramatically impact the false‐positive rate for rare variants. This is due to the fact that rare variants are, by definition, seen infrequently, making it hard to distinguish between errors and real variants. Compounding this problem is the fact that the proportion of errors is likely to get worse, not better, with increasing sample size. One cannot simply scale their way up in order to solve this problem. Understanding these potential pitfalls is a key step in successfully identifying true associations between rare variants and diseases. 相似文献
8.
9.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献
10.
PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)